Discrepancies between the EULAR response criteria and the NICE guidelines for continuation of anti-TNF therapy in RA: A cause for concern?

Rheumatology

Volumn 47, Issue 2, 2008, Pages 180-182

  Jerram, S ^a   Butt, S ^a   Gadsby, K ^a   Deighton, Chris ^a  

^a DERBYSHIRE ROYAL INFIRMARY   (United Kingdom)

Author keywords

Biological therapies; Health policies; Outcome measures; Rheumatoid arthritis

Indexed keywords

TUMOR NECROSIS FACTOR ANTIBODY;

ARTICLE; DISEASE ACTIVITY; DISEASE DURATION; DRUG RESPONSE; HEALTH CARE ORGANIZATION; HUMAN; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DATABASES, FACTUAL; GREAT BRITAIN; HUMANS; PRACTICE GUIDELINES AS TOPIC; REPRODUCIBILITY OF RESULTS; TIME FACTORS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 38649102825     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kem331     Document Type: Article

References (14)

1. Van der Heijde DMFM, Van't Hof MA, Van Riel PLCM et al. Judging disease activity in clinical practice in rheumatoid arthritis: First step in the development of a disease activity score. Ann Rheum Dis 1990;49:916-20.
2. Van der Heijde DMFM, Van't Hof MA, Van Riel PLCM et al. Development of a disease activity score based on judgement in clinical practice by rheumatologists. J Rheumatol 1993;20:570-811.
3. Van der Heijde DMFM, Van't Hof MA, Van Riel, PLCM et al. Validity of singular variables and composite indices for measuring disease activity in rheumatoid arthritis. Ann Rheum. Dis 1992;51:177-81.
4. Welsing PMJ, Landewe RBM, Van Rial PLCM et al. The relationship between disease activity and radiologic progression in patients with rheumatoid arthritis: A longitudinal analysis. Arthritis Rheum 2004;50:2082-93.
5. Preevo MLL, Van't Hof MA, Kuper HH et al. Modified disease activity soores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44-8.
6. Van Gestel AM, Prevoo MLL, Van't Hof MA et al. Development and validation of the European league against rheumatism response criteria for rheumatoid arthritis. Arthritis Rheum 1996;39:34-40.
7. Van Gestel AM, Haagsma CJ, Van Riel PLCM. Validation of rheumatoid arthritis improvement criteria that include simplified joint counts. Arthritis Rheum 1998;41:1845-50.
8. British Society for Rheumatology. Guidelines for prescribing TNF-α blockers in adults with rheumatoid arthritis. London: British Society for Rheumatology, 2001 (www.rheumatology.org.uk).
9. Ledingham J, Deighton C. Update on the British Society ior Rhoumatology guidelines for prescribing TNF-α blockers in adults with rheumatoid arthritis (update of previous guidelines of 2001). Rheumatology 2005;44:157-63,
10. National Institute for Health and Clinical Excellence. Guidance on the use of etanercept and infliximab for the treatment of rheumatoid arthritis. Health Technology Guidance. No. 36. London: National Institute for Health and Clinical Excellence, 2002. http://guidance.nice.org.uk/TA36/guidance/pdf/English
11. National Institute for Health and Clinical Excellence. Adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis (Final Appraisal Determination). 27 November 2006. http://guidance.nice.org.uk/download.aspx.?o=ZN554
12. Hyrich K, Symmons D, Walson K et al. Baseline co-morbidity levels in biologic and standard DMARD treated patients with rheumatoid arthritis: Results from a national patient register. Ann Rheum Dis 2006;65:895-8.
13. Deighton CM, George E, Kiely P, Ledingham J, Luqmaani R, Scott DL. Updating the BSR guidelines for anti-TNF therapy in adult RA (again). Rheumatology 2006;45:649-52.
14. Deighton CM. How should we be using TNF alpha inhibitors in 2007? Musculoskeletal Specialist Library, National Library for Health. http://www.library.nhs.uk/musculoskeletal/viewResource.aspx?resID= 251067&code=69093723fa4d000c25efe5e68cO6930b.